50/FIFTY

Today's stories, rewritten neutrally

FinanceJun 9

Major Corporate Deals and IPO Activity Mark Busy Week for Financial Markets

Several significant corporate transactions and public offerings highlighted market activity, including GSK's $10.6 billion acquisition and multiple fundraising deals.

Synthesized from 14 sources

GSK announced plans to acquire oncology company Nuvalent for $10.6 billion, marking a major expansion of the pharmaceutical giant's cancer treatment portfolio. The acquisition will give GSK ownership of three drug candidates for lung cancer, with two currently under FDA review for potential approval this year.

In the artificial intelligence sector, Apollo and Blackstone raised $35 billion in chip financing for AI company Anthropic, representing one of the largest funding rounds in the AI space. Separately, Applied Digital signed a substantial $5.2 billion lease agreement with a U.S. hyperscaler for AI data center services.

Public market activity also picked up with multiple companies making moves toward or completing public offerings. Indian grocery delivery startup Zepto filed for an IPO, with documents revealing that advertising revenue jumped 151% while overall operating revenue grew 104%, though the company continues to post losses. WhiteHawk Income increased its IPO volume to 7.7 million shares to raise $200.2 million and rebranded as WhiteHawk Minerals.

Additionally, Mission Produce provided updated financial guidance, forecasting $84 million to $88 million in second-half adjusted EBITDA following the close of its Calavo acquisition, with the company targeting $25 million in synergies within 18 months of the deal's completion.

Sources (14)

Bias Scale:
LeftCenterRight
Financial TimesJun 9, 2026, 4:57 PM
GSK’s $10.6bn cancer deal will lead to more
0 · Center
74Trust
0 · Center
90High Trust
0 · Center
78Trust
Wall Street JournalJun 9, 2026, 6:29 AM
GSK to Buy Nuvalent for $10.6 Billion in Oncology Push
0 · Center
88High Trust
0 · Center
91High Trust
Financial TimesJun 9, 2026, 1:03 AM
GSK to buy US cancer biotech Nuvalent for $10.6bn
0 · Center
90High Trust
0 · Center
78Trust

Comments

No comments yet. Be the first!